Navigation Links
AmpliTaq Gold DNA Polymerase from Applied Biosystems

ProductsAmpliTaq Gold DNA Polymerase from Applied Biosystems
Company Applied Biosystems
Item AmpliTaq Gold DNA Polymerase
Price 
Description AmpliTaq Gold® DNA Polymerase is a chemically modified form of AmpliTaq® DNA Polymerase. When the chemical moiety is attached to the enzyme, the enzyme is inactive. During set-up and the first ramp of thermal cycling (when the reaction is going through non-optimal annealing temperatures), the enzyme is inactive. The result is that mis-primed primers are not extended. Once the reaction reaches optimal annealing temperatures, the chemical moiety is cleaved during a heat activation step, releasing active AmpliTaq® DNA enzyme.

The yield of specific product increases because reactants are not wasted in the formation of unintended products. Because AmpliTaq Gold® DNA Polymerase is a chemical hot start enzyme, there is no worry of biological contamination.

AmpliTaq Gold® DNA enzyme's chemical hot-start capability can release active enzyme in a "time-release" manner. With or without a limited up-front heat activation step, active enzyme is released slowly during thermal cycling to match template concentration and increase specificity.
Info Applied BiosystemsApplied Biosystems
850 Lincoln Centre Drive
Foster City, CA 94404

Call Applied Biosystems to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-650-425-3266
Customer Service: 650-638-5800
Fax Number: 650-638-5884
Web Site: http://home.appliedbiosystems.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. AmpliTaq DNA Polymerase with Buffer I from Applied Biosystems
2. AmpliTaq DNA Polymerase, 1,000 units with Buffer I from Applied Biosystems
3. AmpliTaq DNA Polymerase with Buffer II from Applied Biosystems
4. AmpliTaq DNA Polymerase, LD with Buffer I from Applied Biosystems
5. T4 DNA Polymerase from Roche Applied Science
6. T4 DNA Polymerase from Roche Applied Science
7. Poly A Polymerase from Invitrogen
8. iTaq DNA Polymerase, 250 U from Bio-Rad
9. iTaq DNA Polymerase, 5,000 U from Bio-Rad
10. Taq DNA Polymerase, 500 U (2 x 250 U) without dNTP from Bioneer, Inc.
11. T4 DNA Polymerase from Invitrogen
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
interferon-related developmental regulator 2...
...
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Biology Products:
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... Jan. 19, 2017 AquaBounty Technologies, Inc. (AIM: ... productivity in aquaculture and a majority-owned subsidiary of Intrexon ... has completed the listing of its common shares on ... from Intrexon. "AquaBounty,s listing on NASDAQ represents ... our exposure to the U.S. markets as we advance ...
Breaking Biology Technology: